System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Jean-Frédéric Blanc is an expert in Oncology at Centre Hospitalier Universitaire de Bordeaux (France). As of October 2026, ScienceLeadR ranks Jean-Frédéric Blanc in the top 1% of experts worldwide for Liver Neoplasms, Biliary Tract Neoplasms and Carcinoma. Jean-Frédéric Blanc has authored 315 publications, the most recent in 2026, and is an investigator in 59 clinical trials, 19 of them ongoing. SLR score: 1,548 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Jean-Frédéric Blanc Centre Hospitalier Universitaire de Bordeaux France
1 548 ScienceLeadR Reputation 1548

Unlock

Register Login
Network Map

Oncology

Subspecialties: Hepatology - Gastroenterology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2002 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Bordeaux

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 315

Citations

Citations: 43 374 1st author: 18 Last author: 18 Unique author: 2

Main journals

J Clin Oncol 47
J Hepatol 23
Hepatology 17
Eur J Cancer 11
Liver Int 11

Best Journals

J Clin Oncol 20
Lancet Oncol 6
Ann Oncol 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).
PMID 42736101 — carcinoma, hepatocellular, safety, neoplasms, drug therapy, tumor burden, chemotherapy		Dig Liver Dis20260
Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.
PMID 42677015 — carcinoma, hepatocellular, safety, sorafenib, aged, therapeutics		Liver Cancer20260
Implementation and evaluation of an ambulatory care pathway for intra-arterial treatment of primary liver cancer: study protocol for a multicentre randomised controlled hybrid type 1 trial (CHOC).
PMID 42562579 — quality of life, neoplasms, liver, liver neoplasms, ambulatory care, therapeutics		BMJ Open20260
Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.
PMID 42494243 — genes, liver, therapeutics, mutation, prognosis, cholangiocarcinoma		Liver Int20260
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.
PMID 42330996 — liver diseases, hypertension, carcinoma, hepatocellular, bevacizumab, transaminases, drug-related side effects and adverse reactions, therapeutics, ipilimumab, gastrointestinal diseases		Lancet Gastroenterol Hepatol Top journal20265

Clinical Studies 59

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 19
Phase 2 18
N/A 8
Phase 1/Phase 2 6
Phase 1 4
Phase 2/Phase 3 4

By status:

Completed 34
Recruiting 11
Active not recruiting 8
Not yet recruiting 3
Unknown 2
Terminated 1

By type:

Interventional 53
Observational 6

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 1
multicentric5to9 4
multicentricup10 45

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

19 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Evaluation of the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab
2022-502948-13-00 — carcinoma, hepatocellular, safety, immune checkpoint inhibitors, carcinoma		Phase 2Active not recruiting2024
MICROBIOTA MODIFICATION FOR IMMUNO ONCOLOGY IN HEPATOCELLULAR CARCINOMA MOTHER
2023-508201-25-00 — carcinoma, hepatocellular, mothers, microbiota, carcinoma		Phase 2Recruiting2025
Visugromab nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post anti PD (L)1 failure
2025-520675-86-00 — carcinoma, hepatocellular, safety, liver, nivolumab, therapeutics, child, carcinoma		Phase 2Recruiting2026
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
2022-502404-73-00 — safety, adenocarcinoma		Phase 2Recruiting2024
PEHRICCA PErioperative CISGEM plus RILVEGOSTOMIG in High Risk resectable Intrahepatic CholangioCarcinoma
2025-521302-17-00 — cholangiocarcinoma, intrahepatic cholangiocarcinoma		Phase 2/Phase 3Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS